miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 6, 2026

Philip Morris targets 5–7% organic net revenue growth for 2026 while expanding smoke-free leadership

View original at seekingalpha.com
Philip Morris targets 5–7% organic net revenue growth for 2026 while expanding smoke-free leadership Earnings Call Insights: Philip Morris International Inc…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Excise tax changes in Japan and U.S. regulatory developments for ZYN are key drivers for smoke-free volume growth reacceleration

    80% confidence
  • Total net revenues reached over $40 billion in 2025 with 41.5% or close to $17 billion generated by smoke-free business

    80% confidence
  • Cigarette volume forecast to decline by around 3% in 2026

    80% confidence
  • 2025 was another outstanding year for PMI with leadership in smoke-free products and sustained growth

    80% confidence
  • U.S. market deployed different promotion intensity in Q3 and Q4, with some schemes not repeated by PMI decision

    80% confidence
  • IQOS drove core performance with both shipments and adjusted IMS growing around 11%

    80% confidence
  • Both ZYN ex-Nordics and VEEV more than doubled shipment volumes in international markets

    80% confidence
  • Smoke-free shipment and adjusted IMS volumes expected to grow in high single digits in 2026

    80% confidence
  • State excise tax increases on nicotine pouches would be counterproductive to health benefits these products provide

    80% confidence
  • IQOS showing strong performance in Italy, Germany, Spain, and new markets like Taiwan

    80% confidence
  • PMI forecasts 2026 organic net revenue growth of 5% to 7% and organic operating income growth of 7% to 9%

    80% confidence
  • Operating cash flow targeted at around $13.5 billion for 2026

    80% confidence
  • PMI looks forward with confidence to 2026 and beyond

    80% confidence
  • Organic top line and operating income growth were in line with forecast ranges set at start of 2025, and currency-neutral adjusted diluted EPS growth exceeded expectations by 1.7 points

    80% confidence
  • PMI ambitions to continue being very efficient on costs and targeting efficiency from AI in the future

    80% confidence
  • PMI targets leverage ratio of close to 2x by end of 2026

    80% confidence
  • 27 markets surpassed the 50% smoke-free net revenue milestone

    80% confidence
  • Adjusted diluted EPS of $7.54 was at high end of last guidance range despite lower-than-expected currency tailwind

    80% confidence
  • Increased competitive activity in Japan but IQOS strongly holds share and continues growth

    80% confidence
  • Currency-neutral adjusted diluted EPS growth projected at 7.5% to 9.5% for 2026, translating to $8.39 to $8.54 including currency benefits

    80% confidence
  • Japan excise tax will cause some IMS shipment distortions with potential consumer buying ahead, but over longer period PMI will achieve targets

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
Philip Morris targets 5–7% organic net revenue growth for 2026 while expanding smoke-free leadership — Source | Via News | es.VIA.NEWS